At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a ...
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion ...
The early research, presented at the 66th American Society of Haematology (ASH) Annual Meeting and Exposition (Abstract 4), suggests a potentially economical way to enhance CAR T cell function and ...
Denver Post Newsroom: 303-954-1201 or [email protected] Customer Service: Customer service is open Monday-Friday from 6:30 a.m.-5 p.m., Saturday from 7 a.m.-10 a.m. and Sunday from 8:30 a ...
Dec. 5, 2024 — Stem cell transplantation is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a ...
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per ...
Dec. 5, 2024 — The fungus that causes coffee wilt disease repeatedly took up segments of DNA from a related fungal pathogen, which contributed to successive ... Dec. 6, 2024 — A single ...
According to TSA, the stowaway bypassed two identity verification and boarding status stations at John F. Kennedy International Airport.
After hours: December 9 at 4:04:59 PM EST Loading Chart for B ...
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) ...
Researchers report significant progress toward expanding the therapeutic options available for people with non-cancerous blood conditions in five studies presented during the 66th American Society of ...